Journal of AdvancedMedical and Dental Sciences Research

Background:Depomedroxyprogesterone acetate (DMPA) administered through injection stands out as a remarkably safe, convenient, highly effective, reversible, and long-acting method of postpartum contraception, all while having no adverse impact on lactation.Methods:This prospective study involved 60 women who received intramuscular Depomedroxyprogesterone acetate (DMPA) every three months starting six weeks postpartum. Results:In the study, 43.33% of participants fell into the 21-25 age group, while 33.33% were in the 26-30 age bracket. Of the participants, 53.34% were primiparous. The most prevalent side effect was irregular bleeding, affecting 36.67% of individuals, followed by secondary amenorrhea in 20%, weight gain in 7.5%, headaches in 5.83%, and acne in 1.67%. The majority (61.66%) discontinued DMPA after the first and second injections, with 20.84% and 17.5% discontinuing after the third and fourth doses, respectively. The primary reason for discontinuation was side effects, accounting for 68.34%. A notable 16.66% were lost to follow-up, while 15% transitioned to another form of contraception.Despite these findings, the majority of users expressed satisfaction with lactation. No significant blood pressure alterations were observed among DMPA users, and no serious adverse reactions were reported, with none of the women becomingpregnant during DMPA use.Conclusion:The study concluded that InjectableDepomedroxyprogesterone acetate (DMPA) proves to be a secure and highly efficient postpartum contraceptive method without negatively impacting lactation. The importance of pre-use counseling regarding anticipated side effects, coupled with consistent follow-up, emerged as a key factor in enhancing acceptance and continuation rates among users.